US pharmaceutical company Eli Lilly will see a slight turnover increase in Romania to some $19m this year, up from $17.5m in 2002. “We estimate to post turnover amounting to about $18-19m by yearend and a 10%-15% increase next year,” Ovidiu Popescu, corporate affairs manager at Eli Lilly Romania, told Ziarul Financiar. He added the company had reported sales worth $5m in Q3, when, according to market surveys, Eli Lilly ranked 10th among the drugmakers operating in Romania, controlling 3% of the market. ZF
ZF English
Eli Lilly climbs to $19m
US pharmaceutical company Eli Lilly will see a slight turnover increase in Romania to some $19m this year, up from $17.5m in 2002. "We estimate to post turnover amounting to about $18-19m by yearend and a 10%-15% increase next year," Ovidiu Popescu, corporate affairs manager at Eli Lilly Romania, told Ziarul Financiar